Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Videos|June 18, 2021
Improving Life as a Physician
Author(s)Robert Kiltz, MD
You must take care of yourself before you can take care of others.
Advertisement
Robert Kiltz, MD, gives some ideas of how physicians can tend to their own wellness.
Dr Kiltz is an author, motivational speaker, artist, board-certified OB/GYN and reproductive endocrinologist, and Founder and Director of CNY Fertility, one of the largest and most dynamic fertility centers in the country, featured in the Wall Street Journal, Today Show, and CNBC.
Advertisement
Related to this article
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
3
Interventional Options for TRD: ECT, TMS, and Esketamine
4
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
5